Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glasdegib - Pfizer

Drug Profile

Glasdegib - Pfizer

Alternative Names: 1095173-27-5; DAURISMO; PF 04; PF-04449913; PF-4449913

Latest Information Update: 14 Mar 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Grupo Espanol de Trasplante Hematopoyetico y Terapia Celular; H. Lee Moffitt Cancer Center and Research Institute; Pfizer; Yale University
  • Class Antineoplastics; Benzimidazoles; Phenylurea compounds; Piperidines; Small molecules
  • Mechanism of Action Hedgehog cell-signalling pathway inhibitors; SMO protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Acute myeloid leukaemia
  • Phase II Chronic myelomonocytic leukaemia; Myelofibrosis
  • Phase I/II Glioblastoma; Graft-versus-host disease
  • Phase I Haematological malignancies; Solid tumours
  • No development reported Cancer; Myelodysplastic syndromes

Most Recent Events

  • 02 Dec 2020 Pfizer terminates phase III BRIGHT AML 1019 trial in Acute myeloid leukemia (Combination therapy, First-line therapy) in USA, Australia, Austria, Belgium, Canada, China, Japan, Czech Republic, France, Germany, Hungary, Israel, Italy Korea, Mexico, Romania, Russia, UK, Poland, Spain, Sweden, Taiwan (PO) (Pfizer pipeline, December 2020)
  • 28 Nov 2020 No recent reports of development identified for phase-I development in Cancer(In volunteers) in USA (PO, Tablet)
  • 28 Nov 2020 No recent reports of development identified for phase-I development in Haematological-malignancies(Late-stage disease, Monotherapy, Second-line therapy or greater) in Japan (PO, Tablet)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top